These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 30646116

  • 1. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.
    Saloner B, Levin J, Chang HY, Jones C, Alexander GC.
    JAMA Netw Open; 2018 Aug 03; 1(4):e181588. PubMed ID: 30646116
    [Abstract] [Full Text] [Related]

  • 2. Association of Medicaid Expansion With Opioid Overdose Mortality in the United States.
    Kravitz-Wirtz N, Davis CS, Ponicki WR, Rivera-Aguirre A, Marshall BDL, Martins SS, Cerdá M.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1919066. PubMed ID: 31922561
    [Abstract] [Full Text] [Related]

  • 3. Association between state Medicaid expansion status and naloxone prescription dispensing.
    Sohn M, Talbert JC, Delcher C, Hankosky ER, Lofwall MR, Freeman PR.
    Health Serv Res; 2020 Apr 03; 55(2):239-248. PubMed ID: 32030751
    [Abstract] [Full Text] [Related]

  • 4. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD, Jones CM, Smart R, Sheng F, Sorbero M.
    Drug Alcohol Depend; 2021 Apr 01; 221():108569. PubMed ID: 33578296
    [Abstract] [Full Text] [Related]

  • 5. Association of Medicaid Expansion With Cardiovascular Mortality.
    Khatana SAM, Bhatla A, Nathan AS, Giri J, Shen C, Kazi DS, Yeh RW, Groeneveld PW.
    JAMA Cardiol; 2019 Jul 01; 4(7):671-679. PubMed ID: 31166575
    [Abstract] [Full Text] [Related]

  • 6. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
    Mark TL, Parish WJ, Zarkin GA.
    JAMA Netw Open; 2020 Apr 01; 3(4):e203132. PubMed ID: 32310285
    [Abstract] [Full Text] [Related]

  • 7. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H, Slavova S, Freeman PR, Lofwall M, Browning S, Slade E, Bush H.
    Drug Alcohol Depend; 2019 Dec 01; 205():107606. PubMed ID: 31606590
    [Abstract] [Full Text] [Related]

  • 8. Changes in Buprenorphine Treatment After Medicaid Expansion.
    Olfson M, Zhang VS, King M, Mojtabai R.
    Psychiatr Serv; 2021 Jun 01; 72(6):633-640. PubMed ID: 33730878
    [Abstract] [Full Text] [Related]

  • 9. Medicaid Expansion and Prescription Trends: Opioids, Addiction Therapies, and Other Drugs.
    Cher BAY, Morden NE, Meara E.
    Med Care; 2019 Mar 01; 57(3):208-212. PubMed ID: 30629018
    [Abstract] [Full Text] [Related]

  • 10. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H, Hockenberry JM, Pollack HA.
    JAMA Netw Open; 2018 Sep 07; 1(5):e182943. PubMed ID: 30646185
    [Abstract] [Full Text] [Related]

  • 11. Association Between a State Law Allowing Pharmacists to Dispense Naloxone Without a Prescription and Naloxone Dispensing Rates.
    Gangal NS, Hincapie AL, Jandarov R, Frede SM, Boone JM, MacKinnon NJ, Koechlin K, DeFiore-Hyrmer J, Holthusen A, Heaton PC.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1920310. PubMed ID: 32003819
    [Abstract] [Full Text] [Related]

  • 12. Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018.
    Golan OK, Sheng F, Dick AW, Sorbero M, Whitaker DJ, Andraka-Christou B, Pigott T, Gordon AJ, Stein BD.
    Drug Alcohol Depend Rep; 2023 Dec 03; 9():100193. PubMed ID: 37876376
    [Abstract] [Full Text] [Related]

  • 13. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R, Appajosyula S, Deximo C.
    Adv Ther; 2018 Apr 03; 35(4):457-466. PubMed ID: 29623562
    [Abstract] [Full Text] [Related]

  • 14. Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic.
    Alinsky RH, Prichett L, Chang HY, Alexander GC, Stein BD, Saloner B.
    J Adolesc Health; 2022 Aug 03; 71(2):239-241. PubMed ID: 35595609
    [Abstract] [Full Text] [Related]

  • 15. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socias ME, OPTIMA Research Group within the Canadian Research Initiative in Substance MisuseResearch Centre, Centre Hospitalier de l'Université de Montréal, Montreal (Jutras-Aswad, Bruneau, Gagnon, Brissette); Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montreal (Jutras-Aswad); Department of Pharmacology and Toxicology and Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto (Le Foll); Department of Psychiatry, University of Toronto, Toronto (Le Foll, Fischer, Rehm); Dalla Lana School of Public Health, University of Toronto, Toronto (Le Foll, Rehm); Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Center for Addiction and Mental Health (CAMH), Toronto (Le Foll); Acute Care Program, CAMH, Toronto (Le Foll); British Columbia Centre on Substance Use, Vancouver (Ahamad, Wood, Fikowski, Socias); Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver (Ahamad); Department of Family Medicine and Psychiatry, Cumming School of Medicine, University of Calgary, Alberta, Canada (Lim); Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, Montreal (Bruneau, Brissette); Schools of Population Health and Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand (Fischer); Centre for Applied Research in Mental Health and Addiction, Faculty of Health Science, Simon Fraser University, Vancouver (Fischer); Department of Psychiatry, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil (Fischer); Institute for Mental Health Policy Research, CAMH, Toronto (Rehm); Institute of Clinical Psychology and Psychotherapy Centre and Centre for Clinical Epidemiology and Longitudinal Studies, Technische Universität Dresden, Dresden, Germany (Rehm); Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Moscow (Rehm); School of Public Health, University of Alberta, Edmonton, Canada (Wild); Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver (Wood, Socias); Unité de Recherche Clinique Appliquée, Research Centre, Centre Hospitalier Universitaire Sainte-Justine, Montreal (Ledjiar, Masse); Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montreal (Masse)..
    Am J Psychiatry; 2022 Oct 03; 179(10):726-739. PubMed ID: 35702828
    [Abstract] [Full Text] [Related]

  • 16. Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.
    Stein BD, Saloner BK, Golan OK, Andraka-Christou B, Andrews CM, Dick AW, Davis CS, Sheng F, Gordon AJ.
    JAMA Health Forum; 2023 May 05; 4(5):e231102. PubMed ID: 37234015
    [Abstract] [Full Text] [Related]

  • 17. A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients.
    Chang HY, Krawczyk N, Schneider KE, Ferris L, Eisenberg M, Richards TM, Lyons BC, Jackson K, Weiner JP, Saloner B.
    Drug Alcohol Depend; 2019 Aug 01; 201():127-133. PubMed ID: 31207453
    [Abstract] [Full Text] [Related]

  • 18. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States.
    Knudsen HK, Hartman J, Walsh SL.
    Drug Alcohol Depend; 2022 Mar 01; 232():109336. PubMed ID: 35123365
    [Abstract] [Full Text] [Related]

  • 19. Opioid Analgesics in Georgia Medicaid: Trends in Potential Inappropriate Prescribing Practices by Demographic Characteristics, 2009-2014.
    Jayawardhana J, Abraham AJ, Perri M.
    J Manag Care Spec Pharm; 2018 Sep 01; 24(9):886-894. PubMed ID: 30156455
    [Abstract] [Full Text] [Related]

  • 20. Decline in Prenatal Buprenorphine/Naloxone Fills during the COVID-19 Pandemic in the United States.
    O'Donoghue AL, Reichheld A, Anderson TS, Zera CA, Dechen T, Stevens JP.
    J Addict Med; 2018 Sep 01; 17(6):e399-e402. PubMed ID: 37934549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.